Novo Nordisk is moving closer to pursuing official approval to sell its weight-loss pill Wegovy in China, with CEO Mike Doustdar announcing the application is coming “very soon.”
Doustdar made the remarks on Tuesday, signaling the company’s push to establish a stronger foothold in the world’s second-largest pharmaceutical market. The move is seen as an effort to keep pace with competitor Eli Lilly, which has also been targeting China’s growing market for weight-loss treatments.
